Home > Annual Financials > SEQUENT SCIENTIFIC

SEQUENT SCIENTIFIC Financial Statement Analysis
[BOM: 512529|NSE : SEQUENT]

The Revenues of SEQUENT SCIENTIFIC have increased by 3.76% YoY .
The Earnings Per Share (EPS) of SEQUENT SCIENTIFIC has decreased by Negative YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

SEQUENT SCIENTIFIC Last 5 Annual Financial Results
[BOM: 512529|NSE : SEQUENT]

ConsolidatedMar2023
Mar2022
Mar2021
Mar2020
Mar2019
Revenues ₹1,413 Cr₹1,362 Cr₹1,179 Cr₹1,039 Cr₹848 Cr
Expenses ₹1,303 Cr₹1,152 Cr₹1,009 Cr₹914 Cr₹765 Cr
Operating Profit (Excl OI) ₹109 Cr₹210 Cr₹170 Cr₹125 Cr₹83 Cr
Other Income ₹11 Cr₹10 Cr₹10 Cr₹8.67 Cr₹17 Cr
Interest ₹16 Cr₹24 Cr₹36 Cr₹33 Cr₹33 Cr
Depreciation ₹52 Cr₹51 Cr₹51 Cr₹42 Cr₹41 Cr
Profit Before Tax ₹53 Cr₹137 Cr₹94 Cr₹59 Cr₹24 Cr
Profit After Tax ₹45 Cr₹104 Cr₹82 Cr₹57 Cr₹10 Cr
Consolidated Net Profit ₹41 Cr₹95 Cr₹70 Cr₹49 Cr₹422 Cr
Earnings Per Share (Rs)₹-4.86₹1.65₹3.84₹2.81₹1.97
PAT Margin (%)-8.393.107.676.815.37
ROE(%)-18.956.5615.0012.068.63
ROCE(%)-9.717.0116.2412.599.24
Total Debt/Equity(x)0.620.490.310.510.47

Key Financials

Market Cap : ₹ 2,979.0 Cr
Revenue (TTM) : ₹ 1,375.2 Cr
Net Profit(TTM) : ₹ -123.3 Cr
EPS (TTM) : ₹ -4.9
P/E (TTM) : -

Industry Peers & Returns1W1M1Y
SEQUENT SCIENTIFIC -0.9% -21.7% 48.1%
SUN PHARMACEUTICAL INDUSTRIES 3% 2.3% 68.2%
CIPLA 2.5% 0.4% 71.7%
DR REDDYS LABORATORIES -0.2% -4.9% 40.3%
ZYDUS LIFESCIENCES 5% 10.4% 109.1%
DIVIS LABORATORIES -1.6% -7% 23.8%
MANKIND PHARMA NA NA NA
TORRENT PHARMACEUTICALS 2.9% -2.2% 69%
LUPIN 2.8% 0% 147.8%


SEQUENT SCIENTIFIC Revenues
[BOM: 512529|NSE : SEQUENT]

Y-o-Y

3.76 %

5 Yr CAGR

13.62 %

Years Revenues % Change
Mar2023 ₹1,413 Cr
3.76
Mar2022 ₹1,362 Cr
15.47
Mar2021 ₹1,179 Cr
13.46
Mar2020 ₹1,039 Cr
22.58
Mar2019 ₹848 Cr -


SEQUENT SCIENTIFIC Operating Profit
[BOM: 512529|NSE : SEQUENT]

Y-o-Y

-47.90 %

5 Yr CAGR

7.15 %

Years Operating Profit % Change
Mar2023 ₹109 Cr
-47.90
Mar2022 ₹210 Cr
23.26
Mar2021 ₹170 Cr
36.33
Mar2020 ₹125 Cr
50.57
Mar2019 ₹83 Cr -

Operating Margins
Y-o-Y

-49.81 %

5 Yr CAGR

-5.70 %

Years Operating Margin% % Change
Mar2023 7.74%
-49.81
Mar2022 15.42%
6.79
Mar2021 14.44%
20.13
Mar2020 12.02%
22.78
Mar2019 9.79% -

SEQUENT SCIENTIFIC Profit After Tax
[BOM: 512529|NSE : SEQUENT]

Y-o-Y

-57.09 %

5 Yr CAGR

-44.17 %

Years Profit After Tax % Change
Mar2023 ₹41 Cr
-57.09
Mar2022 ₹95 Cr
36.53
Mar2021 ₹70 Cr
43.66
Mar2020 ₹49 Cr
-88.46
Mar2019 ₹422 Cr -

PAT Margins
Y-o-Y

Negative

5 Yr CAGR

Negative

Years PAT Margin(%) % Change
Mar2023 -8.39 %
Negative
Mar2022 3.1 %
-59.58
Mar2021 7.67 %
12.63
Mar2020 6.81 %
26.82
Mar2019 5.37 % -

SEQUENT SCIENTIFIC Earnings Per Share (EPS)
[BOM: 512529|NSE : SEQUENT]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years EPS % Change
Mar2023 ₹-4.86
Negative
Mar2022 ₹1.65
-57.03
Mar2021 ₹3.84
36.65
Mar2020 ₹2.81
42.64
Mar2019 ₹1.97 -

SEQUENT SCIENTIFIC Return on Capital Employed (ROCE)
[BOM: 512529|NSE : SEQUENT]

Y-o-Y

Negative

5 Yr CAGR

Negative

Years ROCE % Change
Mar2023 -9.71%
Negative
Mar2022 7.01%
-56.83
Mar2021 16.24%
28.99
Mar2020 12.59%
36.26
Mar2019 9.24% -

SEQUENT SCIENTIFIC Share Price vs Sensex

Current Share Price : ₹119.4
Current MarketCap: ₹ 2,979.0 Cr
Updated EOD on :Apr 18,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
SEQUENT SCIENTIFIC

-0.9%

-21.7%

48.1%

SENSEX

-2.9%

-0.4%

20%

SEQUENT SCIENTIFIC related INDICES

BSE Indices1W1M1Y
S&P BSE SMALL CAP -1.1% 11.8% 62%
S&P BSE MIDSMALLCAP -1.2% 9.4% 62.3%
S&P BSE ALLCAP -2.2% 3.9% 37%
S&P BSE HEALTHCARE -3.1% 2.5% 51.1%
No NSE index found

You may also like the below Video Courses


FAQ about SEQUENT SCIENTIFIC Financials


How the annual revenues of SEQUENT SCIENTIFIC have changed ?

The Revenues of SEQUENT SCIENTIFIC have increased by 3.76% YoY .

How the Earnings per Share (EPS) of SEQUENT SCIENTIFIC have changed?

The Earnings Per Share (EPS) of SEQUENT SCIENTIFIC has decreased by Negative YoY .